BRIEF-Onconova Therapeutics Preclinical Narazaciclib Data At Sabcs Highlights Differentiated Anti-Tumor Activity

Reuters2023-12-09

Dec 9 (Reuters) - Onconova Therapeutics Inc :

* ONCONOVA THERAPEUTICS’ PRECLINICAL NARAZACICLIB DATA AT SABCS HIGHLIGHTS DIFFERENTIATED ANTI-TUMOR ACTIVITY V. OTHER CDK4/6I’S

* ONCONOVA THERAPEUTICS INC - NARAZACICLIB PROGRESSING TOWARDS RP2D AND PREPARATION FOR REGISTRATIONAL STUDIES, WITH A PLANNED UPDATE IN H1 2024

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

FranKoh
2023-12-09
FranKoh
Will it soar to 2 dollars ?

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2390515898?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-12-09 05:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2390515898","market":"us","top_or_hot":-1,"title":"BRIEF-Onconova Therapeutics Preclinical Narazaciclib Data At Sabcs Highlights Differentiated Anti-Tumor Activity","media":"Reuters","content":"<html><body><p>Dec 9 (Reuters) - Onconova Therapeutics Inc   :</p><p>   * ONCONOVA THERAPEUTICS’ PRECLINICAL NARAZACICLIB DATA AT SABCS HIGHLIGHTS DIFFERENTIATED ANTI-TUMOR ACTIVITY V. OTHER CDK4/6I’S</p><p>   * ONCONOVA THERAPEUTICS INC - NARAZACICLIB PROGRESSING TOWARDS RP2D AND PREPARATION FOR REGISTRATIONAL STUDIES, WITH A PLANNED UPDATE IN H1 2024</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Onconova Therapeutics Preclinical Narazaciclib Data At Sabcs Highlights Differentiated Anti-Tumor Activity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Onconova Therapeutics Preclinical Narazaciclib Data At Sabcs Highlights Differentiated Anti-Tumor Activity\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-12-09 05:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dec 9 (Reuters) - Onconova Therapeutics Inc   :   * ONCONOVA THERAPEUTICS’ PRECLINICAL NARAZACICLIB DATA AT SABCS HIGHLIGHTS DIFFERENTIATED ANTI-TUMOR ACTIVITY V. OTHER CDK4/6I’S   * ONCONOVA ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2390515898","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2390515898","pubTimestamp":1702069774,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Dec 9  - Onconova Therapeutics Inc   :   * ONCONOVA THERAPEUTICS’ PRECLINICAL NARAZACICLIB DATA AT SABCS HIGHLIGHTS DIFFERENTIATED ANTI-TUMOR ACTIVITY V. OTHER CDK4/6I’S   * ONCONOVA THERAPEUTICS INC - NARAZACICLIB PROGRESSING TOWARDS RP2D AND PREPARATION FOR REGISTRATIONAL STUDIES, WITH A PLANNED UPDATE IN H1 2024Source text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药"},"translate_title":"Sabcs的Onconova Therapeutics临床前Narazaciclib数据强调了分化的抗肿瘤活性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ONTX":1},"content_text":"Dec 9 (Reuters) - Onconova Therapeutics Inc   :   * ONCONOVA THERAPEUTICS’ PRECLINICAL NARAZACICLIB DATA AT SABCS HIGHLIGHTS DIFFERENTIATED ANTI-TUMOR ACTIVITY V. OTHER CDK4/6I’S   * ONCONOVA THERAPEUTICS INC - NARAZACICLIB PROGRESSING TOWARDS RP2D AND PREPARATION FOR REGISTRATIONAL STUDIES, WITH A PLANNED UPDATE IN H1 2024Source text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":250114781667448,"gmtCreate":1702082127889,"gmtModify":1702082132078,"author":{"id":"3578479768557192","authorId":"3578479768557192","name":"FranKoh","avatar":"https://static.tigerbbs.com/94104f964346a916676e7e914d93706d","vip":1,"crmLevel":5,"crmLevelSwitch":1,"idStr":"3578479768557192","authorIdStr":"3578479768557192"},"htmlText":"Will it soar to 2 dollars ?&nbsp;","listText":"Will it soar to 2 dollars ?&nbsp;","text":"Will it soar to 2 dollars ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/250114781667448","repostId":2390515898,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":1,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2390515898"}